• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人肝UGT1A1、UGT2B4和UGT2B7参与卡维地洛的葡萄糖醛酸化作用。

Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol.

作者信息

Ohno Akiko, Saito Yoshiro, Hanioka Nobumitsu, Jinno Hideto, Saeki Mayumi, Ando Masanori, Ozawa Shogo, Sawada Jun-ichi

机构信息

Division of Environmental Chemistry, National Institute of Health Sciences, Tokyo 158-8501, Japan.

出版信息

Drug Metab Dispos. 2004 Feb;32(2):235-9. doi: 10.1124/dmd.32.2.235.

DOI:10.1124/dmd.32.2.235
PMID:14744946
Abstract

Carvedilol ((+/-)-1-carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) is metabolized primarily into glucuronide conjugates. In the present study, we identified the human UDP-glucuronosyltransferase (UGT) isoforms involved in the glucuronidation of carvedilol by thin-layer chromatography using microsomes from human liver or insect cells expressing recombinant UGT isoforms. We observed two forms of carvedilol glucuronides, namely G1 and G2, in hepatic microsomes. The glucuronidation of carvedilol was catalyzed by at least three recombinant UGT isoforms: UGT1A1, UGT2B4, and UGT2B7. UGT2B4 formed both G1 and G2, whereas UGT1A1 and UGT2B7 were responsible for the formation of glucuronide G2 and G1, respectively. The enzyme kinetics for carvedilol glucuronidation by UGT1A1, UGT2B4, and UGT2B7 in addition to human liver microsomes were examined by Lineweaver-Burk analysis. The values of Km and Vmax for human liver microsomes were 26.6 microM and 106 pmol/min/mg protein for G1, and 46.0 microM and 44.5 pmol/min/mg protein for G2, respectively. The Km values for UGT1A1, UGT2B4, and UGT2B7 for G1 and G2 (22.1-55.1 microM) were comparable to those of the liver microsomes, whereas the Vmax values were in the range of 3.33 to 7.88 pmol/min/mg protein. The Km and Vmax/Km values for UGT2B4 and UGT2B7 for G1 were similar, whereas UGT2B4 had lower Km and higher Vmax/Km values for G2 compared with those of UGT1A1. These results suggest that G1 formation is catalyzed by UGT2B4 and UGT2B7, whereas G2 is formed by UGT2B4 and UGT1A1. These three hepatic UGT isoforms may have important roles in carvedilol metabolism.

摘要

卡维地洛((+/-)-1-咔唑-4-基氧基)-3-[[2-(邻甲氧基苯氧基)乙基]氨基]-2-丙醇)主要代谢为葡糖醛酸共轭物。在本研究中,我们使用人肝脏微粒体或表达重组UGT同工型的昆虫细胞,通过薄层色谱法鉴定了参与卡维地洛葡糖醛酸化的人尿苷二磷酸葡糖醛酸基转移酶(UGT)同工型。我们在肝微粒体中观察到两种卡维地洛葡糖醛酸化物形式,即G1和G2。卡维地洛的葡糖醛酸化由至少三种重组UGT同工型催化:UGT1A1、UGT2B4和UGT2B7。UGT2B4形成G1和G2,而UGT1A1和UGT2B7分别负责葡糖醛酸化物G2和G1的形成。通过Lineweaver-Burk分析研究了UGT1A1、UGT2B4和UGT2B7以及人肝脏微粒体对卡维地洛葡糖醛酸化的酶动力学。人肝脏微粒体中G1的Km和Vmax值分别为26.6 microM和106 pmol/min/mg蛋白,G2的Km和Vmax值分别为46.0 microM和44.5 pmol/min/mg蛋白。UGT1A1、UGT2B4和UGT2B7对G1和G2的Km值(22.1 - 55.1 microM)与肝脏微粒体的Km值相当,而Vmax值在3.33至7.88 pmol/min/mg蛋白范围内。UGT2B4和UGT2B7对G1的Km和Vmax/Km值相似,而与UGT1A1相比,UGT对G2的Km值较低,Vmax/Km值较高。这些结果表明G1的形成由UGT2B4和UGT2B7催化,而G2由UGT2B以及UGT1A1形成。这三种肝脏UGT同工型可能在卡维地洛代谢中起重要作用。

相似文献

1
Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol.人肝UGT1A1、UGT2B4和UGT2B7参与卡维地洛的葡萄糖醛酸化作用。
Drug Metab Dispos. 2004 Feb;32(2):235-9. doi: 10.1124/dmd.32.2.235.
2
Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7.普萘洛尔在人和食蟹猴肝微粒体中的立体选择性葡萄糖醛酸化:人肝UDP - 葡萄糖醛酸基转移酶同工型UGT1A9、UGT2B4和UGT2B7的作用
Pharmacology. 2008;82(4):293-303. doi: 10.1159/000165100. Epub 2008 Oct 21.
3
Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.多巴胺的区域选择性葡萄糖醛酸化:显著的物种差异及人尿苷二磷酸葡萄糖醛酸基转移酶同工型的鉴定
Drug Metab Dispos. 2005 Mar;33(3):403-12. doi: 10.1124/dmd.104.002667. Epub 2004 Dec 17.
4
Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.UGT1A1和UGT2B7对消旋卡维地洛的立体选择性代谢以及这些酶的突变对葡萄糖醛酸化活性的影响。
Biol Pharm Bull. 2007 Nov;30(11):2146-53. doi: 10.1248/bpb.30.2146.
5
Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.尿苷二磷酸葡萄糖醛酸基转移酶和细胞色素P450 2D6基因多态性对卡维地洛处置个体差异的影响
J Pharm Pharm Sci. 2006;9(1):101-12.
6
Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes.手性卡维地洛对映体在人肝微粒体和肠微粒体介导的外消旋体葡萄糖醛酸化过程中的相互抑制。
Biol Pharm Bull. 2012;35(2):151-63. doi: 10.1248/bpb.35.151.
7
Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.参与双酚A葡萄糖醛酸化的人类UDP-葡萄糖醛酸基转移酶同工型。
Chemosphere. 2008 Dec;74(1):33-6. doi: 10.1016/j.chemosphere.2008.09.053. Epub 2008 Nov 5.
8
Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.参与7-乙基-10-羟基喜树碱葡萄糖醛酸化反应的人肝脏UDP-葡萄糖醛酸基转移酶同工型
Xenobiotica. 2001 Oct;31(10):687-99. doi: 10.1080/00498250110057341.
9
Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.人肝微粒体中反式-3'-羟基可替宁的O-和N-葡萄糖醛酸化作用
Drug Metab Dispos. 2005 Jan;33(1):23-30. doi: 10.1124/dmd.104.001701. Epub 2004 Oct 6.
10
Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.卡维地洛在人肝微粒体和肠微粒体中的立体选择性葡萄糖醛酸化。
Pharmacology. 2012;90(3-4):117-24. doi: 10.1159/000340020. Epub 2012 Jul 18.

引用本文的文献

1
Obesity-related drug-metabolizing enzyme expression alterations in the human liver.人类肝脏中与肥胖相关的药物代谢酶表达变化
Biomed Pharmacother. 2025 Jun;187:118155. doi: 10.1016/j.biopha.2025.118155. Epub 2025 May 12.
2
Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.儿科β受体阻滞剂治疗:儿童、青少年和青年精准治疗的发展和遗传变异综合综述。
Genes (Basel). 2024 Mar 20;15(3):379. doi: 10.3390/genes15030379.
3
The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases.
UDP-葡萄糖醛酸基转移酶基因变异体的功能及其与药物反应和人类疾病的关联。
J Pers Med. 2021 Jun 14;11(6):554. doi: 10.3390/jpm11060554.
4
Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.使用基于生理的药代动力学建模方法优化卡维地洛在肝硬化中的临床应用。
Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):383-396. doi: 10.1007/s13318-016-0353-2.
5
Chronic heart failure: beta-blockers and pharmacogenetics.慢性心力衰竭:β受体阻滞剂与药物遗传学
Eur J Clin Pharmacol. 2009 Jan;65(1):3-17. doi: 10.1007/s00228-008-0566-7. Epub 2008 Oct 7.
6
Stereoselective glucuronidation of carvedilol by Chinese liver microsomes.中国肝微粒体对卡维地洛的立体选择性葡萄糖醛酸化作用。
J Zhejiang Univ Sci B. 2007 Oct;8(10):756-64. doi: 10.1631/jzus.2007.B0756.